Behavioral Effects of the Benzodiazepine-Positive Allosteric Modulator SH-053-2’F-S-CH3 in an Immune-Mediated Neurodevelopmental Disruption Model | Zendy

Juliet Richetto | Zendy; Marie A. Labouesse | Zendy; Michael M. Poe | Zendy; James M. Cook | Zendy; Anthony A. Grace | Zendy; Marco Andrea Riva | Zendy; Urs Meyer | Zendy

Open Access

Behavioral Effects of the Benzodiazepine-Positive Allosteric Modulator SH-053-2’F-S-CH3 in an Immune-Mediated Neurodevelopmental Disruption Model

Author(s) -

Juliet Richetto,

Marie A. Labouesse,

Michael M. Poe,

James M. Cook,

Anthony A. Grace,

Marco Andrea Riva,

Urs Meyer

Publication year - 2015

Publication title -

the international journal of neuropsychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 107

eISSN - 1469-5111

pISSN - 1461-1457

DOI - 10.1093/ijnp/pyu055

Subject(s) - allosteric regulation , dopaminergic , gabaa receptor , allosteric modulator , gabaergic , neuroscience , benzodiazepine , schizophrenia (object oriented programming) , offspring , psychology , gamma aminobutyric acid , dopamine , conditioned place preference , pharmacology , receptor , medicine , inhibitory postsynaptic potential , biology , psychiatry , genetics , pregnancy

Impaired γ-aminobutyric acid (GABA) signaling may contribute to the emergence of cognitive deficits and subcortical dopaminergic hyperactivity in patients with schizophrenia and related psychotic disorders. Against this background, it has been proposed that pharmacological interventions targeting GABAergic dysfunctions may prove useful in correcting such cognitive impairments and dopaminergic imbalances.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research